Telomir Pharmaceuticals, Inc. - Common Stock (TELO)
4.1300
+0.0800 (1.98%)
Telomir Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies that target cellular aging and age-related diseases
The company specializes in the research and development of medications aimed at enhancing telomere function, which plays a crucial role in cellular health and longevity. By leveraging advanced scientific insights, Telomir Pharmaceuticals aims to transform the treatment landscape for conditions such as cancer and degenerative diseases, ultimately striving to improve the quality of life for patients by addressing the underlying mechanisms of aging.
Telomir Pharmaceuticals (NASDAQTELO) announced new preclinical findings demonstrating that its proprietary compound, Telomir-1, fully reverses calcium dysregulation—a key driver of cell death, aging, and disease progression. The study confirmed that Telomir-1 restores calcium homeostasis, reduces oxidative stress, and protects mitochondrial function in multiple human cell lines. The compound showed promise in preventing cellular damage linked to neurodegenerative diseases, metabolic disorders, and viral-induced inflammation. Telomir is advancing preclinical studies to bring Telomir-1 into human trials, aiming to develop a first-in-class therapy for aging-related conditions.
New Study Confirms Telomir-1 Also Reverses Oxidative Stress, Preserves Cellular Integrity, and Prevents Cell Death by Protecting Mitochondria-The Cell's Power Source and Gatekeeper of Life and Death
Telomir Pharmaceuticals (NASDAQTELO) announced a breakthrough with its Telomir-1 platform, successfully stabilizing both Silver(I) (Ag⁺) and highly reactive Silver(II) (Ag²⁺) in a biologically compatible form. This advancement overcomes longstanding stability challenges, paving the way for enhanced antimicrobial treatments, wound care solutions, and infection-resistant medical coatings. With the silver-based medical market projected to reach billions in the coming years, Telomir’s innovation could play a key role in next-generation therapeutics for infection control and tissue regeneration.
MIAMI, FLORIDA / ACCESS Newswire / February 21, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQTELO), or Telomir, a leader in age-reversal science, today announced a breakthrough achievement-Telomir-1 has successfully captured and stabilized both Silver(I) (Ag⁺) and the highly reactive Silver(II) (Ag²⁺) in a biologically compatible form. This milestone overcomes a major limitation in silver-based medical applications, opening the door for advanced antimicrobial treatments, wound care solutions, and infection-resistant medical coatings.
Telomir Pharmaceuticals' Telomir-1 stabilizes Silver(II) for medical use, addressing instability issues in antimicrobial treatments and wound care solutions.
Telomir Pharmaceuticals (NASDAQTELO) announced positive preclinical results demonstrating its lead compound, Telomir-1, significantly reduced reactive oxygen species (ROS) induced by copper and iron exposure in human retinal cell lines. The findings suggest Telomir-1’s potential as a disease-modifying therapy for age-related macular degeneration (AMD) by targeting oxidative stress, a key driver of retinal degeneration. The company plans further in vivo studies to evaluate Telomir-1’s efficacy in AMD, as well as its broader applications in age-related diseases, including Wilson’s disease, cancer, and Alzheimer’s.
MIAMI, FLORIDA / ACCESS Newswire / February 18, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQTELO), or Telomir, a leader in age-reversal science, today announced groundbreaking results from its recent preclinical studies conducted in human retinal cell lines. These studies demonstrated the ability of Telomir-1 to significantly reverse copper and iron-induced elevation of Reactive Oxygen Species (ROS).
Oxidative stress drives aging and is a key factor in diseases like Alzheimer's, Age-related Macular Degeneration (AMD), cardiovascular diseases, cancer, and diabetes. It also plays a critical role in the progression of viral infections, such as avian influenza (bird flu), by exacerbating inflammation and cellular damage. Directly addressing oxidative stress and its consequences is essential to treating the underlying causes of these conditions and mitigating the severity of viral outbreaks.
Telomir Pharmaceuticals (NASDAQTELO), an emerging leader in age-reversal science, announced significant findings from a preclinical progeria lifespan study in collaboration with Nagi Bioscience SA. Using C. elegans nematode models with wrn-1 gene mutations (analogous to human Werner Syndrome), the study demonstrated that Telomir-1 restored lifespan and normalized aging effects, including improved movement velocity and tail amplitude. Telomir-1 targets cellular dysfunction by regulating metal imbalances, reducing oxidative stress, and addressing telomere shortening, offering therapeutic promise for conditions like progeria and age-related diseases. Telomir plans to advance research with in vitro studies on human progeria cell lines.
MIAMI, FL / ACCESSWIRE / January 7, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQTELO) ("Telomir"), an emerging leader in age-reversal science focused on treating the root causes of diseases rather than just their symptoms, announced today potentially groundbreaking findings from a preclinical progeria lifespan study conducted in collaboration with Nagi Bioscience SA. Utilizing C. elegans (nematode) models, in which the study demonstrated restoration of shortened lifespan and normalization of accelerated aging with Telomir-1.
Telomir Pharmaceuticals (NASDAQTELO) announced promising preclinical findings demonstrating the copper-binding capabilities of its Telomir-1 drug candidate, positioning it as a potential treatment for Wilson’s disease and other copper-related disorders. Recent studies highlighted Telomir-1’s ability to selectively bind and regulate copper, iron, and zinc, providing a foundation for addressing Wilson’s disease, a rare genetic condition caused by toxic copper accumulation. The company also outlined its broader research initiatives, including studies on Type 2 diabetes, Alzheimer’s disease, cancer, and metal toxicity. Telomir plans to file an IND application in late 2025, with human clinical trials targeted for 2026, aiming to revolutionize treatments for age-related diseases by addressing their root causes.
MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQTELO), or the "Company", an emerging leader in age-reversal science, today announced significant findings from its copper binding studies with Telomir-1. This is a promising development as the company explores Telomir-1 for the treatment of Wilson's disease and other copper related disorders. The announcement marks an important step forward in Telomir's mission to address critical unmet medical needs while continuing to explore transformative therapies.
Telomir-1 shows potential as a treatment for Wilson's disease and related disorders, with promising preclinical results and potential for orphan drug designation.
Telomir Pharmaceuticals Secures $1 Million At $7 Per Share In No-Warrant, Restricted Stock Deal, Underscoring Investor Confidence With A 20% Premium Valuation
Telomir Pharmaceuticals (NASDAQTELO) has raised $1 million in equity funding from The Starwood Trust through a common stock transaction priced at $7 per share, a 20% premium to the closing price. This follows an undrawn $5 million non-dilutive line of credit from The Starwood Trust earlier this year, reinforcing confidence in Telomir’s strategy. The funding supports Telomir’s innovative pipeline, led by its breakthrough compound, Telomir-1, which has demonstrated preclinical efficacy in reversing age-related conditions, including Type 2 diabetes, by addressing root causes like oxidative stress and telomere shortening. Telomir is also advancing research in Alzheimer’s, cancer, osteoarthritis, and Wilson Disease, positioning itself as a pioneer in age-reversal and chronic disease therapies.
Transaction follows a $5 million non-dilutive credit line from the same trusted partner, further reinforcing Telomir's financial strength and growth potential.
Telomir Pharmaceuticals (NASDAQTELO) announced preclinical findings showcasing the transformative potential of its molecule, Telomir-1, in reversing key parameters of Type 2 diabetes. The study demonstrated significant reductions in fasting glucose levels, improvements in glucose homeostasis, and near pre-diabetic levels of insulin resistance, supported by reduced HOMA-IR values and increased survival rates. Telomir-1’s novel mechanism targets iron metabolism, addressing oxidative stress and beta-cell damage, setting it apart from current symptom-focused diabetes treatments. Telomir plans to expand research into other chronic and age-related diseases, including Alzheimer’s and osteoarthritis, as part of its mission to address root causes of disease.
Building on preclinical success demonstrating age reversal, longevity, and increased healthspan, Telomir-1 appears to address insulin resistance at its root, achieving reversal to near pre-diabetic levels
Telomir Pharmaceuticals (NASDAQTELO) announced promising preclinical results for Telomir-1, a compound designed to reverse biological aging and enhance longevity. In collaboration with Nagi Biosciences, the study utilized advanced microfluidic technology to test Telomir-1 on aging model organisms, demonstrating increased lifespan, improved mobility, and measurable reversal of age-related decline. These findings highlight Telomir-1’s potential in addressing aging and associated diseases, with plans for human clinical trials and expanded research into conditions like progeria and chronic illnesses.
MIAMI, FL / ACCESSWIRE / November 21, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQTELO) ("Telomir" or the "Company"), an emerging leader in age-reversal science, today announced groundbreaking preclinical results confirming the efficacy of Telomir-1, a compound designed to effectively turn back the biological clock and support longevity.
Telomir Pharmaceuticals (NASDAQTELO), a preclinical-stage biotechnology company seeking to lead developments in longevity science through the treatment of age-related conditions, will be spotlighted during the upcoming episode of “Health Uncensored with Dr. Drew.” The show will be broadcast on Fox Business Network at 5:30 p.m. EST on Sept. 29, 2024. Dr. Drew will talk with Telomir Pharmaceuticals special advisor Dr. Michael F. Roizen, MD, about the science of longevity and the importance that telomeres, or the protective end caps of chromosomes, have on the aging process. During the episode, Roizen will explain how TELO’s Telomir-1-a novel small molecule has potential to transform the treatment of age-related conditions and extend healthy human and canine lifespans.
